Managers / Q3 2019 · view latest →
Puissance Capital Management LP
CIK 0001658437 · 950 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10022 · 212-878-3700
Summary
Puissance Capital Management LP reported $45M in U.S.-listed holdings across 7 positions for Q3 2019.
The portfolio is heavily concentrated: VRAYQ alone accounts for 44.3% of reported value.
The book was largely unchanged from Q2 2019.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 70.2% · $31M
- Other · 29.8% · $13M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CRVSCORVUS PHARMACEUTICALS INC | TRIMMED | −246.9K | 38.0K | −$951,000 | $114,000 |
| VRAYQVIEWRAY INC | HELD | +0 | 6.84M | −$40M | $20M |
| EKSO BIONICS HLDGS INC | HELD | +0 | 20.53M | −$15M | $11M |
| KDMNKADMON HLDGS INC | HELD | +0 | 3.02M | +$1M | $8M |
| TRACON PHARMACEUTICALS INC | HELD | +0 | 4.60M | −$1M | $2M |
| BELLEROPHON THERAPEUTICS INC | HELD | +0 | 8.30M | −$972,000 | $4M |
| SCYNEXIS INC | HELD | +0 | 378.8K | −$93,000 | $403,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | VRAYQVIEWRAY INChistory → | COM | 44.27% | $20M | 6.84M |
| 2 | EKSO BIONICS HLDGS INC | COM NEW | 24.28% | $11M | 20.53M |
| 3 | KDMNKADMON HLDGS INChistory → | COM | 16.79% | $8M | 3.02M |
| 4 | BELLEROPHON THERAPEUTICS INC | COM | 8.92% | $4M | 8.30M |
| 5 | TRACON PHARMACEUTICALS INC | COM | 4.59% | $2M | 4.60M |
| 6 | SCYNEXIS INC | COM | 0.90% | $403,000 | 378.8K |
| 7 | CRVSCORVUS PHARMACEUTICALS INC | COM | 0.25% | $114,000 | 38.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2020 | $17M | 5 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $23M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $9M | 6 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $40M | 6 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $45M | 7 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $102M | 7 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $123M | 6 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.